Date published: 2026-4-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Eltrombopag (CAS 496775-61-2)

0.0(0)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
3-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid; SB 497115
Application:
Eltrombopag is an agonist of the c-Mpl (thrombopoietin receptor)
CAS Number:
496775-61-2
Purity:
98%
Molecular Weight:
442.47
Molecular Formula:
C25H22N4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Eltrombopag is an agonist of the c-Mpl (Thrombopoietin (Tpo) receptor), used as treatment for thrombocytopenia.


Eltrombopag (CAS 496775-61-2) References

  1. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.  |  Bussel, JB., et al. 2007. N Engl J Med. 357: 2237-47. PMID: 18046028
  2. Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.  |  Alper, PB., et al. 2008. Bioorg Med Chem Lett. 18: 5255-8. PMID: 18778936
  3. Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.  |  Marsilje, TH., et al. 2008. Bioorg Med Chem Lett. 18: 5259-62. PMID: 18783949
  4. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.  |  Sun, H., et al. 2012. Stem Cell Res. 9: 77-86. PMID: 22683680
  5. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.  |  Kao, YR., et al. 2018. Sci Transl Med. 10: PMID: 30209246
  6. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells.  |  Guenther, KL., et al. 2019. Exp Hematol. 73: 1-6.e6. PMID: 30986494
  7. The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.  |  Vogel, JU., et al. 2019. Cells. 9: PMID: 31861948
  8. Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium.  |  Nevil, G., et al. 2021. Pediatr Hematol Oncol. 38: 8-13. PMID: 32804009
  9. Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein.  |  Zhu, Y., et al. 2020. Acta Pharm Sin B. 10: 1414-1425. PMID: 32963940
  10. The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure.  |  Ding, S., et al. 2020. J Immunol Res. 2020: 1798795. PMID: 33123600
  11. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.  |  Ma, S., et al. 2021. Biochem Pharmacol. 186: 114436. PMID: 33539815
  12. Eltrombopag directly inhibits BAX and prevents cell death.  |  Spitz, AZ., et al. 2021. Nat Commun. 12: 1134. PMID: 33602934
  13. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.  |  Qanash, H., et al. 2021. Cells. 10: PMID: 33810313
  14. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections.  |  Lee, H., et al. 2021. Antibiotics (Basel). 10: PMID: 34827309
  15. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.  |  Guan, Y., et al. 2022. J Clin Invest. 132: PMID: 35085104

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Eltrombopag, 5 mg

sc-207614
5 mg
$263.00

Eltrombopag, 50 mg

sc-207614A
50 mg
$381.00

Eltrombopag, 100 mg

sc-207614B
100 mg
$490.00